Single-centre, single-blinded, randomised, parallel group, feasibility study protocol investigating if mandibular advancement device treatment for obstructive sleep apnoea can reduce nocturnal gastro-oesophageal reflux (MAD-Reflux trial)

• Published in: BMJ open 2023-08, Vol.13 (8), p.e076661-e076661
• Main Authors: O'Toole, Saoirse, Moazzez, Rebecca, Wojewodka, Gabriella, Zeki, Sebastian, Jafari, Jafar, Hope, Katherine, Brand, Andrew, Hoare, Zoe, Scott, Suzanne, Doungsong, Kodchawan, Ezeofor, Victory, Edwards, Rhiannon Tudor, Drakatos, Panagis, Steier, Joerg
• Format: Article
• Language: English
• Subjects: Costs; Feasibility Studies; GASTROENTEROLOGY; Gastroenterology and Hepatology; Gastroesophageal reflux; Health economics; Interdisciplinary aspects; ORAL MEDICINE; Patients; Quality of life; Questionnaires; Sleep apnea; SLEEP MEDICINE; Teeth
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-076661

IntroductionJust under half of patients with obstructive sleep apnoea (OSA) also have gastro-oesophageal reflux disease (GORD). These conditions appear to be inter-related and continual positive airway pressure (CPAP) therapy, the gold standard treatment for OSA to prevent airway collapse, has been shown to reduce GORD. As the impact of mandibular advancement devices, a second-line therapy for OSA, on GORD has yet to be investigated, a feasibility study is needed prior to a definitive trial.MethodsThis will be a single-centre, single-blinded, tertiary-care based, interdisciplinary, parallel randomised controlled study. Potential OSA participants presenting to the sleep department will be pre-screened for GORD using validated questionnaires, consented and invited to receive simultaneous home sleep and oesophageal pH monitoring. Those with confirmed OSA and GORD (n=44) will be randomly allocated to receive either CPAP (n=22) or MAD therapy (n=22). Following successful titration and 3 weeks customisation period, participants will repeat the simultaneous sleep and oesophageal pH monitoring while wearing the device. The number of patients screened for recruitment, drop-out rates, patient feedback of the study protocol, costs of interventions and clinical information to inform a definitive study design will be investigated.Ethics and disseminationHealth Research Authority approval has been obtained from the Nottingham 2 Research Ethics Committee, ref:22/EM/0157 and the trial has been registered on ISRCTN (https://doi.org/10.1186/ISRCTN16013232). Definitive findings about the feasibility of doing 24 hour pH oesophageal monitoring while doing a home sleep study will be disseminated via clinical and research networks facilitating valuable insights into the simultaneous management of both conditions.Trial registration numberISRCTN Reg No: 16013232.